These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

238 related items for PubMed ID: 6117947

  • 1. Neuroleptic drug-induced dopamine receptor supersensitivity: antagonism by L-prolyl-L-leucyl-glycinamide.
    Chiu S, Paulose CS, Mishra RK.
    Science; 1981 Dec 11; 214(4526):1261-2. PubMed ID: 6117947
    [Abstract] [Full Text] [Related]

  • 2. Mesolimbic and striatal dopamine receptor supersensitivity: prophylactic and reversal effects of L-prolyl-L-leucyl-glycinamide (PLG).
    Chiu P, Rajakumar G, Chiu S, Johnson RL, Mishra RK.
    Peptides; 1985 Dec 11; 6(2):179-83. PubMed ID: 2863809
    [Abstract] [Full Text] [Related]

  • 3. Down-regulation of haloperidol-induced striatal dopamine receptor supersensitivity by active analogues of L-prolyl-L-leucyl-glycinamide (PLG).
    Rajakumar G, Naas F, Johnson RL, Chiu S, Yu KL, Mishra RK.
    Peptides; 1987 Dec 11; 8(5):855-61. PubMed ID: 2893360
    [Abstract] [Full Text] [Related]

  • 4. Effect of L-prolyl-L-leucyl-glycinamide (PLG) on neuroleptic-induced catalepsy and dopamine/neuroleptic receptor bindings.
    Chiu S, Paulose CS, Mishra RK.
    Peptides; 1981 Dec 11; 2(1):105-11. PubMed ID: 6113579
    [Abstract] [Full Text] [Related]

  • 5. Enhanced striatal 3H-spiroperidol binding induced by chronic haloperidol treatment inhibited by peptides administered during the withdrawal phase.
    Bhargava HN.
    Life Sci; 1984 Feb 27; 34(9):873-9. PubMed ID: 6142397
    [Abstract] [Full Text] [Related]

  • 6. Effects of prolyl-leucyl-glycinamide and cyclo(leucyl-glycine) on the supersensitivity of dopamine receptors in brain induced by chronic administration of haloperidol to rats.
    Bhargava HN.
    Neuropharmacology; 1984 Apr 27; 23(4):439-44. PubMed ID: 6145116
    [Abstract] [Full Text] [Related]

  • 7. Modulation of CNS dopamine receptors by peptides.
    Mishra RK.
    Prog Neuropsychopharmacol Biol Psychiatry; 1983 Apr 27; 7(4-6):437-42. PubMed ID: 6141599
    [Abstract] [Full Text] [Related]

  • 8. The use of striatal dopaminergic supersensitivity for the evaluation of drugs with possible antidyskinetic properties.
    Valchár M, Krejcí I, Kasafírek E, Schuh J, Dlabac A.
    Pol J Pharmacol Pharm; 1985 Apr 27; 37(3):311-5. PubMed ID: 2866500
    [Abstract] [Full Text] [Related]

  • 9. Striatal dopamine receptor function in morphine-tolerant dependent rats: influence of hypothalamic peptides.
    Bhargava HN.
    NIDA Res Monogr; 1984 Mar 27; 49():320-6. PubMed ID: 6148693
    [No Abstract] [Full Text] [Related]

  • 10. Increase in in vivo (3H) spiperone binding in the rat hippocampal formation and striatum after repeated treatment with haloperidol.
    Bischoff S.
    Experientia; 1981 Mar 27; 37(9):1008-9. PubMed ID: 7297644
    [Abstract] [Full Text] [Related]

  • 11. 3H-Spiroperidol binding to dopamine receptors in rat striatal membranes: influence of loxapine and its hydroxylated metabolites.
    Coupet J, Rauh CE.
    Eur J Pharmacol; 1979 Apr 15; 55(2):215-8. PubMed ID: 456420
    [Abstract] [Full Text] [Related]

  • 12. The residual effect of chronic neuroleptic treatment on the neuroleptic binding assay in rats.
    Wan CW, Peck EJ, Ho BT, Schoolar JC.
    Life Sci; 1983 Mar 14; 32(11):1255-62. PubMed ID: 6834989
    [Abstract] [Full Text] [Related]

  • 13. Attenuation of SCH 23390-induced alteration of striatal dopamine D1 receptor ontogeny by prolyl-leucyl-glycinamide in the rat.
    Kostrzewa RM, Saleh MI.
    Neuropharmacology; 1989 Aug 14; 28(8):805-10. PubMed ID: 2571103
    [Abstract] [Full Text] [Related]

  • 14. Interaction of L-prolyl-L-leucyl glycinamide with dopamine D2 receptor: evidence for modulation of agonist affinity states in bovine striatal membranes.
    Srivastava LK, Bajwa SB, Johnson RL, Mishra RK.
    J Neurochem; 1988 Mar 14; 50(3):960-8. PubMed ID: 2892892
    [Abstract] [Full Text] [Related]

  • 15. MIF-1 attenuates spiroperidol alteration of striatal dopamine D2 receptor ontogeny.
    Saleh MI, Kostrzewa RM.
    Peptides; 1989 Mar 14; 10(1):35-9. PubMed ID: 2568624
    [Abstract] [Full Text] [Related]

  • 16. The effect of melanotropin release inhibiting factor, its metabolites and analogs on [3H]spiroperidol and [3H]apomorphine binding sites.
    Bhargava HN.
    Gen Pharmacol; 1983 Mar 14; 14(6):609-14. PubMed ID: 6141122
    [Abstract] [Full Text] [Related]

  • 17. Chronic domperidone fails to increase striatal spiperone binding sites despite hyperprolactinemia: comparison with chronic haloperidol.
    Morgan DG, Sinha YN, Finch CE.
    Neuroendocrinology; 1984 May 14; 38(5):407-10. PubMed ID: 6728123
    [Abstract] [Full Text] [Related]

  • 18.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 19. Ex vivo 3H-spiroperidol binding to rat striatum and the inhibitory effects of neuroleptics.
    Nakajima T, Egawa E, Kuruma I.
    Jpn J Pharmacol; 1981 Apr 14; 31(2):159-64. PubMed ID: 6118446
    [Abstract] [Full Text] [Related]

  • 20. Effect of chronic sulpiride on striatal spiperone binding.
    Bannet J, Gillis S, Ebstein RP, Belmaker RH.
    Int Pharmacopsychiatry; 1980 Apr 14; 15(6):334-7. PubMed ID: 7298264
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 12.